Almirall misses third-quarter profit view even as sales rise
Spanish dermatology drugmaker Almirall reported third-quarter 2026 profit below its own outlook, though sales grew, according to its earnings call.
Almirall, the Spanish pharmaceutical company focused on dermatology, fell short of its profit outlook for the third quarter of 2026, even as its sales increased. The shortfall was highlighted in the company's earnings call, a transcript of which was published by.
The results were measured against the profit view the company had previously set for the period. While revenue moved higher, profit did not reach the level Almirall had signaled, a gap that is likely to draw investor attention given how closely markets track drugmakers' ability to convert sales growth into earnings.
The available material does not specify how large the profit miss was, nor the precise rate of sales growth. It also does not explain what drove the shortfall, whether any revised guidance was issued, or which products and markets accounted for the increase in sales. The exact date of the call is not stated in the supplied details.
Almirall is one of Spain's better-known specialist pharmaceutical companies, with a portfolio concentrated on skin conditions. Companies in the sector frequently weigh investment in research and commercial expansion against near-term margins, so a gap between rising sales and expected profit can reflect a range of operating factors. Further detail from the company's reporting would be needed to determine which of those applied in this quarter.
Source: investing.com
5
